← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Lineage Cell Therapeutics LCTX $248M	58	0	0%	$57.7M
27	ATHX 27 DELISTED Athersys, Inc. Common Stock ATHX	57	+17	+43%	$43.5M
28	28 Fortress Biotech FBIO $63M	57	-3	-5%	$22.3M
29	29 Arbutus Biopharma ABUS $836M	50	+26	+108%	$174M
30	30 Veracyte VCYT $3.54B	42	+6	+17%	$140M
31	31 Opus Genetics IRD $314M	35	+17	+94%	$12.9M
32	32 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	35	+21	+150%	$31.1M
33	33 DELISTED Carisma Therapeutics CARM	32	+32	–	$185M
34	34 Imunon IMNN $5.84M	30	+5	+20%	$10.2M
35	35 uniQure QURE $1.52B	26	+26	–	$52M
36	36 Neurogene NGNE $473M	23	+23	–	$59.6M
37	37 Pluri PLUR $12.2M	22	+2	+10%	$3.59M
38	38 Fate Therapeutics FATE $223M	21	+5	+31%	$92.8M
39	39 Vericel Corp VCEL $2.05B	20	0	0%	$2.66M
40	40 Eterna Therapeutics ERNA $2.39M	5	0	0%	$5.69M
41	AGTC 41 DELISTED Applied Genetic Technologies Corporation AGTC	1	+1	–	$999K
42	42 DELISTED Scorpius Holdings, Inc. SCPX	1	0	0%	$5.48M
43	43 Qiagen QGEN $9.54B	0	-1	-100%	$0
44	44 Abeona Therapeutics ABEO $255M	–	–	–	–
45	45 Adicet Bio ACET $44.9M	–	–	–	–
46	ACHL 46 DELISTED Achilles Therapeutics ACHL	–	–	–	–
47	47 DELISTED Arcellx ACLX	–	–	–	–
48	ADAP 48 DELISTED Adaptimmune Therapeutics ADAP	–	–	–	–
49	49 Adaptive Biotechnologies ADPT $3.86B	–	–	–	–
50	50 DELISTED Adverum Biotechnologies ADVM	–	–	–	–